The urokinase receptor system as strategic therapeutic target: Challenges for the 21st century

Current Pharmaceutical Design

Volumn 17, Issue 19, 2011, Pages 1872-1873

  Degryse, Bernard ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; TUMOR MARKER; UROKINASE RECEPTOR;

CANCER THERAPY; CARCINOGENESIS; FIBRINOLYSIS; HEMATOPOIETIC STEM CELL; HUMAN; INFLAMMATION; INNATE IMMUNITY; LANGUAGE DEVELOPMENT; MEDICAL RESEARCH; PHARMACEUTICS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL MOBILIZATION; TRANSLATIONAL RESEARCH;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM; DRUG DESIGN; HUMANS; NEOPLASM INVASIVENESS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; STEM CELLS; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 80051692211     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796718161     Document Type: Review

References (8)

1. MacFarlane RG, Pillig, J. Fibrinolytic activity of normal urine. Nature 1947; 159: 779.
2. Sobel GW, Mohler SR, Jones NW, Dowdy ABC, Guest MM. Urokinase: an activator of plasma profibrinolysin extracted from urine. Am J Physiol 1952; 171: 768-769.
3. Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi, F, Assoian RK. Differentiation-enhanced binding of the amino terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 1985; 82: 4939-4943.
4. Vassalli J-D, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator urokinase. J Cell Biol 1985; 100: 88-92.
5. Selleri C, Montuori N, Ricci P, et al. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 2005; 105: 2198-2205.
6. Royer-Zemmour B, Ponsole-Lenfant M, Gara H, et al. Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wildtype and mutant SRPX2 with the plasminogen activator receptor uPAR. Hum Mol Genet 2008; 17: 3617-3630.
7. Archinti M, Britto M, Eden G, Furlan F, Murphy R, Degryse B. The urokinase receptor in the central nervous system. CNS Neurol Disord Drug Targets 2011; 10: 271-294.
8. Degryse B, Neels JG, Czekay RP, Aertgeerts K, Kamikubo Y, Loskutoff DJ. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 2004; 279: 22595-22604.